athenahealth Lets Patients Bring Their Records Into Anthropic's Claude

Good morning, HealthTech insiders. AI is moving deeper into healthcare, from helping patients understand their medical records to detecting complications in intensive care and advancing drug development.

On Monday, athenahealth launched athenaPatient MCP, allowing US Claude Pro and Max users to securely share selected medical records with Anthropic's AI assistant. Ceribell expanded its EEG platform to monitor delirium alongside seizures, supported by a new Medicare payment. Meanwhile, OpenAI-backed Biossil acquired Theriva's antibiotic-degrading enzyme portfolio for $350,000 upfront.

Today's Signal looks at three developments reshaping how healthcare information is accessed, how patients are monitored, and how promising drug assets find new owners.

In today's Signal:

• athenahealth opens athenaOne patient records to Anthropic's Claude through athenaPatient MCP, with patients choosing which data categories to share and able to revoke access at any time.

• Ceribell commercially launches AI EEG delirium monitoring on its seizure platform, with a CMS add-on payment of up to $2,171 per eligible case effective October 1.

• Biossil buys Theriva's antibiotic-degrading enzyme portfolio, led by SYN-004 (ribaxamase), for $350,000 upfront and up to $91M in milestones.

• Plus: Privia buys an ACO with 36,000+ attributed lives for about $36M, Porter acquires Pareto Intelligence, and Specific Biologics raises $35M.

In partnership with

Nobody's coming to approve your idea

People assume that real businesses get built by other people with more resources. It's how great ideas get stuck in notes apps and conversations.

But you don't need six months and a developer's salary to validate your concept. You just need a weekend. Describe what you want to exist and Lovable builds it: a real site, a real product, ready to accept real payments from real customers. Not a mockup to show people. An actual thing they can use.

You don't need anyone's sign-off to get started. Take $5 off your first month.

Find out this weekend

Discount of $5 applies to first month of any paid plan. You need to sign up via this webpage in order to claim the discount. The discount applies to new and returning users without an active paid plan. Terms apply.

PATIENT DATA AND AI
1. athenahealth Lets Patients Bring Their Records Into Anthropic's Claude

On November 2, athenahealth launched athenaPatient MCP, a server built on the Model Context Protocol that connects Anthropic's Claude to the athenaOne platform. US users on Claude Pro and Max plans can add the connector in their Claude settings, sign in with their athenahealth patient portal credentials, and ask questions about their own records in plain language.

The details:

• Patients choose what Claude can see: lab results, medications, vitals, health conditions, diagnostic reports, immunizations, visit history, allergies, procedures and care plans. Credentials are not shared with Claude, data is encrypted in transit, and access can be revoked at any time, per athenahealth.

• Paul Brient, athenahealth's chief product and operations officer, told Fierce Healthcare the company will limit access to AI assistants that do not use patient information to train their models. "Claude is the first connection we've enabled for athenaPatient MCP, but it's not intended to be the only one," he said. "It's not our job to decide which AI assistant patients should use."

• It lands in a crowded lane. OpenAI's ChatGPT for Healthcare integrates with Epic for authorized clinicians, and Oracle's patient portal lets patients chat with their record on OpenAI models. Fierce cites an August Pew Research Center survey in which 34% of US adults had used AI assistants for health-related purposes.

The Signal: The interesting choice is what athenahealth did not build. Instead of its own patient chatbot, it built a permissioned pipe to the assistant patients already use. That makes the EHR a data utility for consumer AI, and it moves the hard questions outside the practice: what the assistant says about a lab value, who answers the follow-up message, and whether the practice ever sees the conversation. MCP is becoming the plug. Governance is still being written.

NEUROMONITORING
2. Ceribell Launches AI EEG Delirium Monitoring on Its Seizure Platform

Ceribell (Nasdaq: CBLL) announced on November 2 the commercial launch of delirium monitoring on its point-of-care EEG platform. The same headband and hardware hospitals use for seizure detection now continuously analyze brain activity for patterns associated with delirium, following an FDA 510(k) clearance in December 2025 and a pilot across multiple hospitals.

The details:

• Ceribell cites delirium in about 30% of ICU patients and up to 80% of mechanically ventilated patients, and says the hypoactive subtype often goes unrecognized because bedside assessments are intermittent and subjective. The system alerts clinicians to support screening alongside bedside evaluations. Ceribell describes it as the first and only FDA-cleared device to aid in delirium screening and monitoring.

• CMS granted a New Technology Add-on Payment (NTAP) of up to $2,171 per eligible Medicare inpatient case, effective October 1, 2026. MassDevice first reported the NTAP decision on August 3.

• Stanford's Dr. Juliana Barr: "Continuous, objective EEG-based information gives clinicians another tool to screen for and monitor delirium in individual patients." CEO Jane Chao, PhD, calls the goal "establishing a new neurological vital sign."

The Signal: This is a land-and-expand play on installed hardware. Hospitals that already bought Ceribell for seizures can add a second indication without a second device, and the NTAP softens the cost for Medicare inpatients. The harder sell is clinical: delirium has few proven treatments, so the value of an earlier alert depends on what the ICU team does next. Expect buyers to ask for outcome data, not just detection data.

AI DRUG DEVELOPMENT
3. OpenAI-Backed Biossil Buys Theriva's Shelved Antibiotic-Protection Drugs for $350,000 Upfront

Theriva Biologics (NYSE American: TOVX) announced on November 2 that it sold its antibiotic-degrading enzyme portfolio to Biossil Labs, a Toronto-based company that describes itself as AI-native. The portfolio is led by SYN-004 (ribaxamase), an oral enzyme designed to break down certain IV antibiotics in the gut so they do not damage the microbiome.

The details:

• Theriva received $350,000 upfront at closing and is eligible for up to $3M in regulatory milestones, up to $88M in sales milestones, and low single-digit royalties capped at $250M. Biossil takes on all future development and commercialization costs. The deal also includes SYN-007, an oral reformulation, and assets related to SYN-006 (carbapenemase).

• In a 412-patient Phase 2b trial of patients on IV ceftriaxone, SYN-004 protected the gut microbiome and lowered the incidence of C. difficile infection, per Theriva. Biossil will continue a Phase 1b/2a study at Washington University in transplant recipients, paused after 2 of 3 cohorts.

• Fierce Biotech reports Biossil exited stealth in April with $70M from OpenAI and Founders Fund and specializes in buying drug candidates that have underperformed. Earlier deals include a $105M agreement for a Summit Therapeutics antibiotic in July and Pfizer's sickle cell candidate rivipansel.

The Signal: The headline number is up to $91M. The real number is $350,000. Shelved clinical assets with human data are cheap when the seller needs to focus its cash, and an AI-native buyer is betting it can pick which ones deserve a second life. The model is capital-light at the front and expensive later. The test is not the AI, but whether any of these rescued drugs reaches approval.

👀 WHAT WE'RE WATCHING NEXT

• Who athenahealth connects next: Brient said Claude is the first assistant but not the only one, without naming the next. Watch whether the connector reaches ChatGPT or Gemini users, and whether practices get any view of what patients asked.

• The CY 2027 Physician Fee Schedule final rule: CMS published the proposed rule on July 16 and the final rule had been expected around November 1. Watch for remote monitoring, digital mental health and software-related payment changes that take effect January 1.

• Ceribell's delirium uptake: Watch the company's next earnings commentary for the number of hospitals that switch on delirium monitoring, and for any outcome data from the pilot sites, not just detection data.

💰 FOLLOW THE MONEY

The deals:

• Privia Health: Paid approximately $36M in cash for Cano Health's ACO business, adding more than 36,000 attributed Medicare lives starting in 2027.

• Specific Biologics: Raised a $35M Series A led by Hatteras Venture Partners to advance its ALS gene-editing program.

• Clinics On Cloud: Secured $12.5M (₹120 crore) in Series A funding from Dubai-based Model42.

• Bioliberty: Added $3.3M in funding, bringing the Edinburgh company's Series A total to $13.5M.

• Biossil: Paid $350,000 upfront to acquire a portfolio of drugs previously tested in Phase 2b clinical trials.

The pattern: Capital is flowing toward established patient networks, clinical development and healthcare technology, but deal sizes tell different stories. Privia's $36M acquisition buys immediate scale, while biotech investors are backing longer-term clinical potential. Biossil's $350,000 upfront payment highlights another strategy: securing access to clinical-stage assets without committing substantial capital at the outset.

📆 UPCOMING HEALTHTECH EVENTS

• BIO-Europe 2026: November 9 to 11, 2026 · Koelnmesse, Cologne, Germany

  Europe's largest biopharma partnering meeting, where asset sales and licensing deals like Biossil's are negotiated. Digital partnering days follow on November 17 and 18.

• SCCM 2027 Critical Care Congress: March 14 to 16, 2027 · San Diego Convention Center, San Diego, CA

  The Society of Critical Care Medicine's annual meeting, the natural venue for ICU delirium and neuromonitoring data.

• ViVE 2027: March 14 to 17, 2027 · Music City Center, Nashville, TN

  The digital health leadership event run by HLTH and CHIME, where health system CIOs and vendors will be debating AI access to patient data.

🛠️ Trending HealthTech AI Tools

• Sentira Single Cell. 10x Genomics launched it on November 2: an agentic analysis tool for Chromium single-cell data, powered by Anthropic's Claude and run on 10x Cloud. Researchers ask questions in natural language and get back reproducible notebooks with methods and code, on usage-based credit pricing.

• Welldoc Cares. Launched November 2 alongside Welldoc's extension into early-stage dementia: a consent-based, view-only companion app that lets family caregivers see shared health insights, medication and habit tracking, and alerts. Available through participating health plans, health systems and life sciences partners.

• Hippocratic AI Polaris 6 Ultra. Released November 2 for patient-facing voice agents. In 2,778 clinician-reviewed production calls, the company reports misheard medications or symptoms fell from 1.19 to 0.20 per 100 calls, and every planning decision is logged in a clinician-facing Safety Portal. Company-reported figures.

🛠️ Trending HealthTech AI Startups

• Octopath AI: A UCL spinout that analyses routine H&E and immunohistochemistry slides at single-cell resolution in under two minutes, giving pathologists quantitative cell, density and spatial measurements. It raised £1.5M in combined seed investment and grant funding, led by TwinPath Ventures and including a £500,000 Innovate UK grant. Strategic interest: quantitative pathology is becoming the data layer for precision oncology.

• Bioliberty: An Edinburgh company whose Lifehub Clinic system pairs a soft robotic glove with software to help stroke survivors regain upper-limb movement. Its $3.3M Series A extension (Nov 2), backed by TGH Ventures, Ballad Ventures and 25M Health, takes the round to $13.5M for a US rollout. Strategic interest: hospital venture arms are backing rehab hardware they already test.

• Clinics On Cloud: Raised a $12.5M (₹120 crore) Series A from Dubai-based Model42 to build out its microclinic network and AI-driven diagnostics, and to expand from the UAE into Africa, the US and Southeast Asia. Strategic interest: point-of-care diagnostics built for emerging markets are attracting Gulf capital.

DECISION INTELLIGENCE

Highlights: Deep Dives & Industry Reports

1. The Record Leaves the Building: athenahealth, Claude and the Rise of Patient-Directed AI Access. A permissioned connector instead of a proprietary chatbot: what athenaPatient MCP changes for practices, privacy and the EHR business model.

2. A Second Indication on the Same Headband: Ceribell, Delirium and the Economics of ICU Neuromonitoring. An FDA-cleared delirium aid, a Medicare add-on payment and an installed seizure base: what has to be true for continuous delirium monitoring to become standard care.

3. Buying Second Chances: Biossil, Theriva and the AI-Native Bet on Shelved Drugs. $350,000 upfront for a Phase 2b-tested portfolio: why discarded clinical assets are cheap, what an AI-native buyer adds, and where the model can fail.

That's it for today!

A record that travels to the assistant a patient already uses, an EEG that adds a second job without a second device, and a shelved drug portfolio bought for $350,000 upfront. Each one is a bet on context: the data, the workflow or the human evidence that makes a decision possible.

Here is the tension: the more context moves to tools outside the clinic, the less the clinic sees. When a patient's AI assistant reads a lab result first, who is responsible for what happens next?

See you tomorrow,

Dr. Dereck Mush, MD, MBA

The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.

Was this email forwarded to you? Sign up here.